Medicine
Visipaque 160000 mg/500 mL injection
Visipaque 160000 mg/500 mL injection is a prescription medicine containing Iodixanol for intravascular use, marketed by GE Healthcare, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. Discard any product that is inadvertently frozen, as freezing…
Key facts
- Active ingredient (INN)
- Iodixanol
- Brand
- Visipaque
- Strength
- 160000 mg/500 mL
- Dosage form
- Injection
- Route
- Intravascular
- Packs
- 10 bottles of 500 mL
- Marketing authorisation holder
- GE Healthcare
- Manufacturer
- GE Healthcare
- Origin register
- US FDA, United States
- Storage
- Do not freeze. Discard any product that is inadvertently frozen, as freezing may compromise the closure integrity of the immediate container. Store VISIPAQUE at controlled room temperature, 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). VISIPAQUE may be stored in a contrast media warmer for up to one month at 37°C (98.6°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V08AB09 Iodixanol
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 May 2006
- Identifiers
- DailyMed set ID 2d964c13-88ad-43be-88d4-a3a7ea4d5b5eNDC 0407-2223Application NDA020808
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 bottle, plastic in 1 box / 500 mL in 1 bottle, plastic | 0407-2223-23 | GE Healthcare | 1 May 2006 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 22 March 1996 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Iodixanol
Clinical summary
Iodixanol is a radiographic contrast agent indicated for vISIPAQUE injection is a radiographic contrast agent indicated for the following, among other approved uses. It is available as injection for intravascular use. MedsAcross supplies Iodixanol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about IodixanolFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Visipaque prescribing information (GE Healthcare) · U.S. National Library of Medicine, DailyMed
Need Visipaque 160000 mg/500 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.